Market Cap 2.90B
Revenue (ttm) 0.00
Net Income (ttm) -182.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,020,500
Avg Vol 777,228
Day's Range N/A - N/A
Shares Out 46.11M
Stochastic %K 86%
Beta 1.50
Analysts Strong Sell
Price Target $96.55

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 394 5230
Address:
Building 17, Suite 102b 221 Crescent Street, Waltham, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:51 AM
$APGE: The stock closed at $65.5, indicating a strong upward trend. The RSI of 76.11 suggests it is overbought, which may lead to a price correction. The 30-day moving average (MA30) at 54.74 and the 50-day moving average (MA50) at 48.12 indicate that the stock has been trending higher over the short to medium term, reinforcing bullish sentiment. However, the proximity to the 60-day high of 67.57 raises caution for potential pullbacks. Directional bias: Bullish in the short term but cautious due to overbought conditions. Suggested entry: Consider entering on a pullback to around $63.50. Stop: Set a stop loss at $62.00 to manage risk. Targets: First target at $67.00 (near the 60D high), and a second target at $70.00, anticipating further bullish momentum if the stock breaks above resistance. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 1:14 AM
$APGE: The last close at $62.97 indicates a strong position, but the RSI of 76.61 suggests overbought conditions, which may lead to a pullback. The MA30 at $53.89 and MA50 at $47.56 show a bullish trend, supporting the current price level. However, the proximity to the 60D high of $64.87 raises caution, as it could trigger profit-taking. Directional bias is cautiously bullish, given the strong moving averages, but the high RSI indicates potential short-term weakness. Suggested entry: $61.50 to capture potential dips. Stop loss: $58.80 to manage risk below recent support levels. Targets: First target at $64.00 (near 60D high) and second target at $66.00 if momentum continues. Monitor for any signs of reversal as price approaches the high. https://privateprofiteers.com
0 · Reply
Gemola
Gemola Nov. 14 at 4:46 PM
$APGE Double doji sandwich. boolish
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 3:56 PM
breakout buzz $CDTX $RVMD $APGE $OWLT $CELC all tapping fresh 52-week highs. biotech acting like it found an extra gear today. what’s driving the surge? full breakdown inside. https://stocksrunner.com/news/2025-11-14-52-week-high-breakout-stocks-to-watch-right-now
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:47 AM
$APGE: The last close at $62.97 indicates a strong position, but the RSI of 76.61 suggests overbought conditions, which may lead to a pullback. The MA30 at $53.89 and MA50 at $47.56 show a bullish trend, supporting the current price level. However, the proximity to the 60D high of $64.87 raises caution, as it could trigger profit-taking. Directional bias is cautiously bullish, given the strong moving averages, but the high RSI indicates potential short-term weakness. Suggested entry: $61.50 to capture potential dips. Stop loss: $58.80 to manage risk below recent support levels. Targets: First target at $64.00 (near 60D high) and second target at $66.00 if momentum continues. Monitor for any signs of reversal as price approaches the high. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:53 AM
$APGE: The last close at $62.95 indicates a strong position, but the RSI at 75.33 suggests the stock is overbought, which may lead to a potential pullback. The MA30 at 52.32 and MA50 at 46.55 indicate a bullish trend, but the absence of a MA200 limits long-term trend analysis. The stock is near its 60D high of 63.84, which could act as a resistance level. Directional bias is cautiously bullish, but with high RSI, a correction could occur. Suggested entry is at $61.50 to capitalize on any potential retracement. Set a stop loss at $59.50 to manage risk. Target 1 is $64.00, just above the 60D high, and Target 2 is $65.50, allowing for further upside if momentum continues. Monitor for any signs of reversal as the stock approaches these levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:29 AM
$APGE: The last close at $62.95 indicates a strong position, but the RSI at 75.33 suggests the stock is overbought, which may lead to a potential pullback. The MA30 at 52.32 and MA50 at 46.55 indicate a bullish trend, but the absence of a MA200 limits long-term trend analysis. The stock is near its 60D high of 63.84, which could act as a resistance level. Directional bias is cautiously bullish, but with high RSI, a correction could occur. Suggested entry is at $61.50 to capitalize on any potential retracement. Set a stop loss at $59.50 to manage risk. Target 1 is $64.00, just above the 60D high, and Target 2 is $65.50, allowing for further upside if momentum continues. Monitor for any signs of reversal as the stock approaches these levels. https://privateprofiteers.com
0 · Reply
miller1m
miller1m Nov. 11 at 7:23 PM
$APGE absolutely a takeout candidate for big pharma. My prediction $180 plus eventually might happen, could be a bidding war here
0 · Reply
Pika_Capital
Pika_Capital Nov. 11 at 4:24 PM
$APGE what a run boyz. Oh wait, there is barely anyone here 😂
1 · Reply
d_risk
d_risk Nov. 10 at 4:28 PM
$APGE - Apogee Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors APGE’s latest 10-Q risk factors expand disclosures on third-party reliance, regulatory and patent risks, cybersecurity, global operations, financial institution exposure, and macroeconomic/geopolitical threats, while adding new risks on misconduct, tax, acquisitions, and product liability; litigation and analyst coverage risks removed. #Biotechnology #MacroeconomicRisk #GlobalOperations #Cybersecurity #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-Q/2025-11-10
0 · Reply
Latest News on APGE
Apogee Therapeutics to Participate in Upcoming Conferences

Nov 3, 2025, 7:30 AM EST - 12 days ago

Apogee Therapeutics to Participate in Upcoming Conferences


Apogee Therapeutics: Engineering Biologic Dominance

Apr 14, 2025, 8:04 AM EDT - 7 months ago

Apogee Therapeutics: Engineering Biologic Dominance


Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 29, 2024, 1:00 PM EST - 1 year ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day


PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:51 AM
$APGE: The stock closed at $65.5, indicating a strong upward trend. The RSI of 76.11 suggests it is overbought, which may lead to a price correction. The 30-day moving average (MA30) at 54.74 and the 50-day moving average (MA50) at 48.12 indicate that the stock has been trending higher over the short to medium term, reinforcing bullish sentiment. However, the proximity to the 60-day high of 67.57 raises caution for potential pullbacks. Directional bias: Bullish in the short term but cautious due to overbought conditions. Suggested entry: Consider entering on a pullback to around $63.50. Stop: Set a stop loss at $62.00 to manage risk. Targets: First target at $67.00 (near the 60D high), and a second target at $70.00, anticipating further bullish momentum if the stock breaks above resistance. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 1:14 AM
$APGE: The last close at $62.97 indicates a strong position, but the RSI of 76.61 suggests overbought conditions, which may lead to a pullback. The MA30 at $53.89 and MA50 at $47.56 show a bullish trend, supporting the current price level. However, the proximity to the 60D high of $64.87 raises caution, as it could trigger profit-taking. Directional bias is cautiously bullish, given the strong moving averages, but the high RSI indicates potential short-term weakness. Suggested entry: $61.50 to capture potential dips. Stop loss: $58.80 to manage risk below recent support levels. Targets: First target at $64.00 (near 60D high) and second target at $66.00 if momentum continues. Monitor for any signs of reversal as price approaches the high. https://privateprofiteers.com
0 · Reply
Gemola
Gemola Nov. 14 at 4:46 PM
$APGE Double doji sandwich. boolish
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 3:56 PM
breakout buzz $CDTX $RVMD $APGE $OWLT $CELC all tapping fresh 52-week highs. biotech acting like it found an extra gear today. what’s driving the surge? full breakdown inside. https://stocksrunner.com/news/2025-11-14-52-week-high-breakout-stocks-to-watch-right-now
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:47 AM
$APGE: The last close at $62.97 indicates a strong position, but the RSI of 76.61 suggests overbought conditions, which may lead to a pullback. The MA30 at $53.89 and MA50 at $47.56 show a bullish trend, supporting the current price level. However, the proximity to the 60D high of $64.87 raises caution, as it could trigger profit-taking. Directional bias is cautiously bullish, given the strong moving averages, but the high RSI indicates potential short-term weakness. Suggested entry: $61.50 to capture potential dips. Stop loss: $58.80 to manage risk below recent support levels. Targets: First target at $64.00 (near 60D high) and second target at $66.00 if momentum continues. Monitor for any signs of reversal as price approaches the high. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:53 AM
$APGE: The last close at $62.95 indicates a strong position, but the RSI at 75.33 suggests the stock is overbought, which may lead to a potential pullback. The MA30 at 52.32 and MA50 at 46.55 indicate a bullish trend, but the absence of a MA200 limits long-term trend analysis. The stock is near its 60D high of 63.84, which could act as a resistance level. Directional bias is cautiously bullish, but with high RSI, a correction could occur. Suggested entry is at $61.50 to capitalize on any potential retracement. Set a stop loss at $59.50 to manage risk. Target 1 is $64.00, just above the 60D high, and Target 2 is $65.50, allowing for further upside if momentum continues. Monitor for any signs of reversal as the stock approaches these levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:29 AM
$APGE: The last close at $62.95 indicates a strong position, but the RSI at 75.33 suggests the stock is overbought, which may lead to a potential pullback. The MA30 at 52.32 and MA50 at 46.55 indicate a bullish trend, but the absence of a MA200 limits long-term trend analysis. The stock is near its 60D high of 63.84, which could act as a resistance level. Directional bias is cautiously bullish, but with high RSI, a correction could occur. Suggested entry is at $61.50 to capitalize on any potential retracement. Set a stop loss at $59.50 to manage risk. Target 1 is $64.00, just above the 60D high, and Target 2 is $65.50, allowing for further upside if momentum continues. Monitor for any signs of reversal as the stock approaches these levels. https://privateprofiteers.com
0 · Reply
miller1m
miller1m Nov. 11 at 7:23 PM
$APGE absolutely a takeout candidate for big pharma. My prediction $180 plus eventually might happen, could be a bidding war here
0 · Reply
Pika_Capital
Pika_Capital Nov. 11 at 4:24 PM
$APGE what a run boyz. Oh wait, there is barely anyone here 😂
1 · Reply
d_risk
d_risk Nov. 10 at 4:28 PM
$APGE - Apogee Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors APGE’s latest 10-Q risk factors expand disclosures on third-party reliance, regulatory and patent risks, cybersecurity, global operations, financial institution exposure, and macroeconomic/geopolitical threats, while adding new risks on misconduct, tax, acquisitions, and product liability; litigation and analyst coverage risks removed. #Biotechnology #MacroeconomicRisk #GlobalOperations #Cybersecurity #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-Q/2025-11-10
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 1:34 PM
$APGE (+2.4% pre) Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 https://ooc.bz/l/83839
0 · Reply
Quantumup
Quantumup Nov. 10 at 11:41 AM
Oppenheimer reiterated $NKTR Outperform/$98 $APGE $CRVS $REGN $SNY LLY ABBV Here's what Oppenheimer said in its note to investors: Following the 3Q update on Thursday, NKTR presented additional findings from the REZOLVE-AD Ph2b study of rezpeg in atopic dermatitis in a late-breaking oral presentation at ACAAI. New results showed that, across dose cohorts, rezpeg treatment demonstrated significant and clinically meaningful improvements in prespecified ACQ-5 scores in AD patients who reported a history of asthma. We view the new findings as further strengthening rezpeg's differentiated profile for AD treatment, as we await results from the maintenance part of the study in 1Q26. Near term, we anticipate topline results from the Ph2 REZOLVE-AA study in alopecia areata in Dec., which could unlock additional upside potential given an arguably low bar for biologics in this untapped indication. We update our model and maintain Outperform.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 11:56 AM
$APGE Current Stock Price: $54.36 Contracts to trade: $55 APGE Nov 21 2025 Call Entry: $3.69 Exit: $7.32 ROI: 98% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 5:45 PM
Craig-Hallum updates rating for Apogee Therapeutics ( $APGE ) to Buy, target set at 109.
0 · Reply
IN0V8
IN0V8 Nov. 3 at 2:53 PM
$APGE bUY RBC raises target price to $70 from $60
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 2:38 PM
RBC Capital has updated their rating for Apogee Therapeutics ( $APGE ) to Outperform with a price target of 70.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:24 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:43 PM
Mizuho has adjusted their stance on Apogee Therapeutics ( $APGE ), setting the rating to Outperform with a target price of 105.
0 · Reply
Rvazstocksfl
Rvazstocksfl Oct. 21 at 12:27 PM
$APGE wow 🤩
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
1 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 1:21 AM
$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting
0 · Reply
Pika_Capital
Pika_Capital Oct. 11 at 12:02 PM
$PTGX proceeds will be redeployed into $IMVT, $APGE (possibly more $GMAB ) and across bunch of other names in pfolio. May reenter $BHVN again but not sure, it's a lower conviction name going into PDUFa.
2 · Reply